Regional trends in average years of potential life lost (AYPLL) secondary to prostate cancer deaths among Caucasians and African Americans treated by surgery or radiation
To study regional trends in average years of potential life lost (AYPLL) among Caucasians (CA) and African Americans (AA) with prostate cancer (Pca) who received radical prostatectomy or radiation therapy among four different regions in the US as well as across different tumor grades. Years of potential life lost is defined as the difference between a predetermined end-point age and the age at death for a death that occurred prior to that end age, hence the AYPLL is calculated by dividing the total YPLL by the total number of patients died.
The surveillance epidemiology and end results (SEER) database was used to identify Pca patients who were CA or AA and who have received radical prostatectomy or radiation therapy. Study duration was divided into four decades; 1973–1982 (D1), 1983–1992 (D2), 1993–2002 (D3), 2003–2012 (D4). Examined regions were; North East (NE), North central (NC), South and West. Tumor grade was classified into; well/moderately differentiated (WD/MD) and poorly/undifferentiated (PD/UD) groups. Differences in AYPLL among CA and AA in each of these variables were compared.
Overall, compared to CA, AA were diagnosed and died earlier from Pca. AA had higher AYPLL to Pca than CA. In both tumor grade groups, progressive increase in AYPLL among AA compared to CA was noted over the last three decades. In the WD/MD group, except for the South region, the highest recorded difference in AYPLL between AA and CA was in D4. In the PD/UD group, a similar difference in AYPLL between AA and CA was noted in all regions. The difference in AYPLL was higher in the PD/UD group than the WD/MD group.
Racial disparity between AA and CA existed across the examined regions. It is more pronounced in advanced tumor grades. The differences were more significant in the last decade.
KeywordsProstate cancer Race Years of life lost Regional Racial disparity
Average years of potential life lost
Moderately differentiated tumor
Poorly differentiated tumor
Years of potential life lost
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 10.Wu XC, Yu Q, Andrews PA, Ranganath P, Qiao B, Ajani U, Wohler B, Zhang Z (2010) Comparisons of directly coded SEER Summary Stage 2000 and collaborative staging derived SEER summary stage 2000. J Regist Manag 37(4):137–140Google Scholar
- 12.Kochanek KD, Xu J, Murphy SL, Minino AM, Kung HC (2011) Deaths: final data for 2009. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics. Natl Vital Stat Syst 60(3):1–116Google Scholar
- 14.Han Y, Rand KA, Hazelett DJ, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Schumacher FR, Berndt SI, Wang Z, Xu J, Rohland N, Reich D, Tandon A, Pasaniuc B, Allen A, Quinque D, Mallick S, Notani D, Rosenfeld MG, Jayani RS, Kolb S, Gapstur SM, Stevens VL, Pettaway CA, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, John EM, Murphy AB, Signorello LB, Carpten J, Leske MC, Wu SY, Hennis AJM, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Witte JS, Casey G, Lubwama A, Pooler LC, Sheng X, Coetzee GA, Cook MB, Chanock SJ, Stram DO, Watya S, Blot WJ, Conti DV, Henderson BE, Haiman CA (2016) Prostate cancer susceptibility in men of african ancestry at 8q24. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv431 Google Scholar
- 15.Powell IJ, Bock CH, Ruterbusch JJ, Sakr W (2010) Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 183(5):1792–1796. https://doi.org/10.1016/j.juro.2010.01.015 CrossRefGoogle Scholar
- 16.Schreiber D, Levy EB, Schwartz D, Rineer J, Wong A, Rotman M, Weiss JP (2014) Impact of race in a predominantly African-American population of patients with low/intermediate risk prostate cancer undergoing radical prostatectomy within an equal access care institution. Int Urol Nephrol 46(10):1941–1946. https://doi.org/10.1007/s11255-014-0773-3 CrossRefGoogle Scholar
- 18.Barocas DA, Grubb R III, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED (2013) Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer 119(12):2223–2229. https://doi.org/10.1002/cncr.28042 CrossRefGoogle Scholar
- 19.Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D’Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL (2014) Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. Urology 84(2):386–392. https://doi.org/10.1016/j.urology.2014.05.009 CrossRefGoogle Scholar
- 22.Chu DI, Moreira DM, Gerber L, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ (2012) Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 118(20):4999–5007. https://doi.org/10.1002/cncr.27456 CrossRefGoogle Scholar
- 24.Tyson MD, Andrews PE, Etzioni DA, Ferrigni RG, Humphreys MR, Swanson SK, Castle EK (2013) Marital status and prostate cancer outcomes. Can J Urol 20(2):6702–6706Google Scholar
- 28.Chen Y-W, Mahal BA, Muralidhar V, Nezolosky M, Beard CJ, Den RB, Feng FY, Hoffman KE, Martin NE, Orio PF, Nguyen PL (2016) Association between treatment at a high-volume facility and improved survival for radiation-treated men with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 94(4):683–690. https://doi.org/10.1016/j.ijrobp.2015.12.008 CrossRefGoogle Scholar
- 30.Wang C, Raldow A, King CR, Kupelian PA, Nickols N, Chang AJ, Steinberg ML, Spratt DE, Nguyen PL, Kishan AU (2018) Racial disparity in androgen deprivation therapy utilization for men with high-risk prostate cancer treated with intensity-modulated radiation therapy in the modern era—a SEER-medicare linked database analysis. Int J Radiat Oncol Biol Phys 102(3):e147–e148. https://doi.org/10.1016/j.ijrobp.2018.07.286 Google Scholar
- 31.Trinh Q-D, Sun M, Sammon J, Bianchi M, Sukumar S, Ghani KR, Jeong W, Dabaja A, Shariat SF, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI (2012) Disparities in access to care at high-volume institutions for uro-oncologic procedures. Cancer 118(18):4421–4426. https://doi.org/10.1002/cncr.27440 doiCrossRefGoogle Scholar
- 32.Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schroder FH, Roobol MJ (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int 110(11):1672–1677. https://doi.org/10.1111/j.1464-410X.2012.11434.x CrossRefGoogle Scholar
- 35.Schreiber D, Chhabra A, Rineer J, Weedon J, Schwartz D (2015) A population-based study of men with low-volume low-risk prostate cancer: does African-American race predict for more aggressive disease? Clin Genitourin Cancer 13(4):e259–e264. https://doi.org/10.1016/j.clgc.2015.02.006 CrossRefGoogle Scholar
- 36.Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR (2016) Pathological and biochemical outcomes among African-American and Caucasian men with low risk prostate cancer in the SEARCH database: implications for active surveillance candidacy. J Urol 196(5):1408–1414. https://doi.org/10.1016/j.juro.2016.06.086 CrossRefGoogle Scholar
- 38.Blair A, Fraumeni JF (1978) Geographic patterns of prostate cancer in the United States. J Natl Cancer Inst 61(6):1379–1384Google Scholar
- 40.Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA (2014) Plasma vitamin D and prostate cancer risk: results from the selenium and Vitamin E cancer prevention trial. Cancer Epidemiol Biomarkers Prev 23(8):1494–1504. https://doi.org/10.1158/1055-9965.EPI-14-0115 CrossRefGoogle Scholar